Harmeet S Sidhu

US Patent:

6355242, Mar 12, 2002

Filed:

Feb 9, 2000

Appl. No.:

09/500500

Inventors:

Milton J. Allison - Ames IA
Harmeet Sidhu - Gainesville FL

Assignee:

Ixion Biotechnology, Inc. - Alachua FL

International Classification:

A01N 6300

US Classification:

424 934, 424 931, 424 941, 424 945, 435183, 435193, 435196, 4352521

Abstract:

This invention provides materials and procedures for the delivery of selected strains of bacteria and/or oxalate-degrading enzymes to the intestinal tracts of persons and/or domestic or zoological animals who are at increased risk for oxalate related disease because they have lost, or have inadequate concentrations of these bacteria. The administration of these bacteria and/or the relevant enzyme removes oxalate from the intestinal tract and thus reduces the amount of oxalate available for absorption and reduces the risk for oxalate related disease.

US Patent:

6699469, Mar 2, 2004

Filed:

Mar 8, 2002

Appl. No.:

10/093686

Inventors:

Milton J. Allison - Ames IA
Harmeet Sidhu - Gainesville FL

Assignee:

Ixion Biotechnology, Inc. - Alachua FL

International Classification:

A01N 6300

US Classification:

424 934, 424 931, 424 941, 424 945, 435193, 435191, 4352521

Abstract:

This invention provides materials and procedures for the delivery of selected strains of bacteria and/or oxalate-degrading enzymes to the intestinal tracts of persons and/or domestic or zoological animals who are at increased risk for oxalate related disease because they have lost, or have inadequate concentrations of these bacteria. The administration of these bacteria and/or the relevant enzyme removes oxalate from the intestinal tract and thus reduces the amount of oxalate available for absorption and reduces the risk for oxalate related disease.

US Patent:

6709820, Mar 23, 2004

Filed:

Apr 9, 2001

Appl. No.:

09/829094

Inventors:

Ammon B. Peck - Gainesville FL
Harmeet Sidhu - Gainesville FL

Assignee:

University of Florida Research Foundation, Inc. - Gainesville FL

International Classification:

C12Q 168

US Classification:

435 6, 435 911, 435 912, 536 231, 536 243, 536 2433

Abstract:

The subject invention concerns the novel use of formyl-CoA transferase enzyme together with oxalyl-CoA decarboxylase enzyme for the detection and measurement of oxalate in biological samples. The use of the enzyme system according to the subject invention results in the conversion of oxalate into carbon dioxide and formate. Because the production of formate is directly correlated to the concentration of oxalate present in a sample, the determination of the resulting formate concentration provides an accurate, sensitive and rapid means for detecting even low levels of oxalate. The subject invention further concerns the cloning, sequencing and expression of the genes that encode the formyl-CoA transferase enzyme and the oxalyl-CoA decarboxylase enzyme of. The subject invention also concerns methods for detecting the presence of organisms in a sample, and the polynucleotide probes and primers used in the detection method.

US Patent:

8431122, Apr 30, 2013

Filed:

Jul 2, 2009

Appl. No.:

12/497275

Inventors:

Harmeet Sidhu - Gainesville FL, US
Qingshan Li - Gainesville FL, US
Aaron Blake Cowley - Gainesville FL, US
Carl-Gustaf Golander - Uppsala, SE

Assignee:

Oxthera Intellectual Property AB - Uppsala

International Classification:

A61K 38/00
A61K 38/54
A61K 38/44
C12N 9/88
C12N 9/10
C12N 9/06
C07H 21/06

US Classification:

424 945, 424 942, 424 944, 435232, 435193, 435191, 536 232

Abstract:

The present invention comprises methods and compositions for the reduction of oxalate in humans, and methods for the purification and isolation of recombinant oxalate reducing enzyme proteins. The invention provides methods and compositions for the delivery of oxalate-reducing enzymes in particle compositions. The compositions of the present invention are suitable in methods of treatment or prevention of oxalate-related conditions.

US Patent:

8486389, Jul 16, 2013

Filed:

Jun 15, 2004

Appl. No.:

10/868242

Inventors:

Harmeet Sidhu - Gainesville FL, US
Milton J. Allison - Ames IA, US

Assignee:

Oxthera, Inc. - Alachua FL
The Milton J. Allison Revocable Trust - Ames IA

International Classification:

A61K 35/74

US Classification:

424 944, 435183

Abstract:

The present invention comprises methods and compositions for the reduction of oxalate in humans, animals and plants. For example, the invention provides methods and compositions for the delivery of one ore more oxalate-reducing enzymes to the intestinal tracts of persons and animals. The methods and compositions can be used in treating and preventing oxalate-related conditions.

US Patent:

8545836, Oct 1, 2013

Filed:

Dec 14, 2006

Appl. No.:

11/639388

Inventors:

Poonam Kaul - Gainesville FL, US
Harmeet Sidhu - Gainesville FL, US

Assignee:

Oxthera, Inc. - Alachua FL

International Classification:

A01N 63/00

US Classification:

424 934, 424 931

Abstract:

The present invention comprises methods and compositions for the reduction of oxalate in humans, animals and plants. For example, the invention provides methods and compositions for the delivery of one or more oxalate-reducing pharmaceutical compositions to the intestinal tracts of persons and animals. The methods and compositions can be used in treating and preventing oxalate-related conditions. A composition of the invention comprises an oral delivery vehicle comprising an oxalate degrading bacteria, one or more cryopreserving agents and one or more excipients. A composition of the invention is enteric coated and has a suitable shelf-life and acceptable properties to avoid negative impact from gastric fluid when it is orally administered.

US Patent:

20030113308, Jun 19, 2003

Filed:

Oct 7, 2002

Appl. No.:

10/266718

Inventors:

Harmeet Sidhu - Gainesville FL, US

International Classification:

A61K038/43

US Classification:

424/094100, 604/265000

Abstract:

The subject invention provides materials and methods for reducing oxalate concentrations in fluids. In a preferred embodiment, the oxalate concentration in biological fluids is reduced. Specifically exemplified herein are stents, catheters, and dialysis membranes which have been modified to degrade oxalate in surrounding fluids. In additional embodiments, oxalate is degraded in other fluids including fermentation broths. Specifically exemplified in the context of fermentation broths is the removal of oxalate from fluids involved in the brewery process.

US Patent:

20040038286, Feb 26, 2004

Filed:

Sep 8, 2003

Appl. No.:

10/658564

Inventors:

Ammon Peck - Gainesville FL, US
Harmeet Sidhu - Gainesville FL, US

International Classification:

C12Q001/68
C07H021/04
C12N009/88
C12N001/21
C12N015/74

US Classification:

435/006000, 435/069100, 435/232000, 435/252300, 435/320100, 536/023200

Abstract:

The subject invention concerns the novel use of formyl-CoA transferase enzyme together with oxalyl-CoA decarboxylase enzyme for the detection and measurement of oxalate in biological samples. The use of the enzyme system according to the subject invention results in the conversion of oxalate into carbon dioxide and formate. Because the production of formate is directly correlated to the concentration of oxalate present in a sample, the determination of the resulting formate concentration provides an accurate, sensitive and rapid means for detecting even low levels of oxalate. The subject invention further concerns the cloning, sequencing and expression of the genes that encode the formyl-CoA transferase enzyme and the oxalyl-CoA decarboxylase enzyme of The subject invention also concerns methods for detecting the presence of organisms in a sample, and the polynucleotide probes and primers used in the detection method.